A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer

British Journal of Cancer

Volumn 65, Issue 2, 1992, Pages 275-281

  Rankin, E M ^a   Mill, L ^a   Kaye, S B ^a   Atkinson, R ^b   Cassidy, L ^c   Cordiner, J ^d   Cruickshank, D ^e   Davis, J ^f   Duncan, I D ^g   Fullerton, W ^e   Habeshaw, T ^a   Kennedy, J ^c   Kennedy, R ^g   Kitchener, H ^d   MacLean, A ^d   Paul, J ^a   Reed, N ^a   Sarker, T ^e   Soukop, M ^c   Swapp, G H ^e   Symonds, R P ^a   more..

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d WESTERN INFIRMARY   (United Kingdom)

^e ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^f STOBHILL HOSPITAL   (United Kingdom)

^g NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CHLORAMBUCIL; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD CELL COUNT; CANCER SURVIVAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHLORAMBUCIL; COMPARATIVE STUDY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; LEUKOPENIA; MIDDLE AGE; NEOPLASM STAGING; OVARIAN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; THROMBOCYTOPENIA;

EID: 0026547073     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1992.55     Document Type: Article

References (23)

1. ADVANCED OVARIAN CANCER TRIALISTS GROUP (1991). Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br. Med.J., 303, 884-893.
2. ALBERTS, D., GREEN, S., HANNIGAN, E. & 7 others (1989). Improved efficacy of carboplatin (carboP)/cyclophosphamide (CPA) vs cisplatin (cisP)/CPA: preliminary report of a phase III, randomized trial in stages III-IV, suboptimal ovarian cancer (OV CA). Proc. Am. Soc. Clin. Oncol., 8, 151 (Abstract).
3. BELANI, C.P., EGORIN, M.J., ABRAMS, J.S. & 4 others (1989). A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide. J. Clin. Oncol., 7, 1896.
4. CALVERT, A.H., NEWELL, D.R., GUMBRELL, L.A. & 7 others (1989). Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7, 1748.
5. DEMBO, A.J. (1986). Controversy over combination chemotherapy in advanced ovarian cancer: what we learn from reports of matured data. J. Clin. Oncol., 4, 1573.
6. EGORIN, M., JODRELL, D., CANETTA, R. & 6 others (1991). Tumour response and toxicity in ovarian cancer correlates with carboplatin area under the curve. Proc. Amer. Soc. Clin. One., 10, 184.
7. EDMONSON, J.H., MCCORMACK, G.M., WIEAND, H.S. & 11 others (1989). Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens. J. Natl Cancer Inst., 81, 1500.
8. EGORIN, M.J., VAN ECHO, D.A., OLMAN, E.A., WHITACRE, M.Y., FORREST, A. & AISNER, J. (1985). Prospective validation of a pharmacologically based dosing scheme for the cis-diammine-dichloro-platinum (II) analogue diamminecyclobutanedicarboxy-latoplatinum. Cancer Res., 45, 6502.
9. EVANS, B.D., RAJU, K.S., CALVERT, A.H., HARLAND, S.J. & WILT-SHAW, E. (1983). Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat. Rep., 67, 997.
10. FISH, R.G., ADAMS, M., SHELLY, M.D. & 4 others (1987). Validity of a dosing scheme for carboplatin. Proc. Am. Soc. Clin. Oncol., 6, 21.
11. GRUPPO INTEREGIONALE COPPERATIVO ONCOLOGICO GINECO-LOGICA (1987). Randomised comparison of cisplatin with cyclo-phosphamide/cisplatin and with cyclophosphamide/doxorubicin/ cisplatin in advanced ovarian cancer. Lancet, 2, 353.
12. GYNAECOLOGICAL GROUP, CLINICAL ONCOLOGICAL SOCIETY OF AUSTRALIA, Sydney Branch, Ludwig Institute for Cancer Research (1986). Chemotherapy of advanced ovarian adenocarcinoma: a randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin. Gynecol. Oncol., 23, 1.
13. HARDING, M., KENNEDY, R., MILL, L. & 5 others (1988). A pilot study of carboplatin (JM8, CBDCA) and chlorambucil in combination for advanced ovarian cancer. Br. J. Cancer, 58, 640.
14. HRYNUIK, W.M. (1987). Average relative dose intensity and the impact on design of clinical trials. Semin. Oncol., 14, 65.
15. MANGIONI, C., BOLIS, G., PECORELLI, S. & 10 others (1989). Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J. Natl Cancer Inst., 81, 1464.
16. OZOLS, R.F. & YOUNG, R.L. (1984). Chemotherapy of ovarian cancer. Semin. Oncol., 11, 251.
17. OZOLS, R.F. (1985). The case for combination chemotherapy in the treatment of advanced ovarian cancer. J. Clin. Oncol., 3, 1445.
18. OZOLS, R.F., OSTCHEGA, Y., MYERS, C.E. & YOUNG, R.C. (1985). High dose cisplatin in hypertonic saline in refractory ovarian cancer. J. Clin. Oncol., 3, 1246.
19. SEROV, S.F., SCULLY, R.E. & SOBIN, L.H. (1973). International histological classification of tumours No. 9. Histological typing of ovarian tumours. WHO: Geneva, p. 10-21.
20. TEN BOKKEL HUININK, W.W., VAN DER BURG, M.E.L., VAN OOSTE-ROM, A T., DALESIO, O., ROTMENSZ, N. & VERMORKEN, J.B. (1987). Carboplatin replacing cisplatin in combination chemotherapy for ovarian cancer. A large scale randomized phase III trial of the Gynecological Cancer Cooperative Group of the EORTC. Proc. Am. Soc. Clin. Oncol., 6, 118 (Abstract).
21. WHO HANDBOOK FOR REPORTING RESULTS OF CANCER TREATMENT (1979). WHO Offset Publication, number 48, WHO: Geneva.
22. WILLIAMS, C.J., MEAD, G.M., MACBETH, F.R. & 8 others (1985). Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J. Clin. Oncol., 3, 1455.
23. YOUNG, R.C., HUBBARD, S.P. & de VITA, V.T. (1974). The chemotherapy of ovarian cancer. Cancer Treat. Rev., 1, 99.